The Value of Anti-angiogenics in Head and Neck Cancer Therapy
Authors:
- 1 October 2019
- book chapter
- Published by Springer Nature
- p. 477-494
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancerAnnals of Oncology, 2016
- Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).Journal of Clinical Oncology, 2015
- Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neckAnnals of Oncology, 2012
- Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).Journal of Clinical Oncology, 2012
- New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)Medical Oncology, 2012
- Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck CancerJournal of Clinical Oncology, 2011
- Phase II study of sunitinib malate in head and neck squamous cell carcinomaInvestigational New Drugs, 2009
- Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer modelAnnals of Oncology, 2009
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyThe Lancet Oncology, 2009
- Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic modelBritish Journal of Cancer, 2008